Edwards Lifesciences Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Operations
(in millions, except per share information; unaudited)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net sales | $1,553.1 | $1,354.4 | $4,498.0 | $4,053.7 |
| Cost of sales | 345.2 | 262.9 | 991.2 | 825.3 |
| Gross profit | 1,207.9 | 1,091.5 | 3,506.8 | 3,228.4 |
| Selling, general, and administrative expenses | 514.6 | 421.4 | 1,482.3 | 1,297.3 |
| Research and development expenses | 280.7 | 253.4 | 811.5 | 781.9 |
| Certain litigation expenses | 90.4 | 10.8 | 116.8 | 27.8 |
| Change in fair value of contingent consideration liabilities | (12.5) | — | (12.5) | — |
| Restructuring charges and separation costs (Note 3) | 0.1 | 32.9 | 8.5 | 32.9 |
| Intangible assets impairment charges | 40.0 | — | 40.0 | — |
| Other operating (income) expense, net | (12.5) | 22.4 | (52.9) | 22.4 |
| Operating income, net | 307.1 | 350.6 | 1,113.1 | 1,066.1 |
| Interest income, net | (38.6) | (24.3) | (112.5) | (56.3) |
| Loss on impairment (Note 6) | — | — | 47.1 | — |
| Other non-operating income, net | (2.7) | (27.9) | (4.0) | (35.6) |
| Income from continuing operations before provision for income taxes | 348.4 | 402.8 | 1,182.5 | 1,158.0 |
| Provision for income taxes | 56.1 | 40.7 | 190.7 | 107.0 |
| Net income from continuing operations | 292.3 | 362.1 | 991.8 | 1,051.0 |
| (Loss) income from discontinued operations, net of tax | (2.0) | 2,707.3 | (13.6) | 2,734.4 |
| Net income | 290.3 | 3,069.4 | 978.2 | 3,785.4 |
| Net loss attributable to noncontrolling interest | (0.8) | (1.4) | (4.1) | (3.6) |
| Net income attributable to Edwards Lifesciences Corporation | $291.1 | $3,070.8 | $982.3 | $3,789.0 |
| Share information (Note 13) | ||||
| Earnings (loss) per share: | ||||
| Basic | ||||
| Continuing operations | $0.50 | $0.61 | $1.70 | $1.76 |
| Discontinued operations | $— | $4.53 | $(0.02) | $4.55 |
| Basic earnings per share | $0.50 | $5.14 | $1.68 | $6.31 |
| Diluted | ||||
| Continuing operations | $0.50 | $0.61 | $1.70 | $1.75 |
| Discontinued operations | $— | $4.52 | $(0.03) | $4.54 |
| Diluted earnings per share | $0.50 | $5.13 | $1.67 | $6.29 |
| Weighted-average number of common shares outstanding: | ||||
| Basic | 584.7 | 597.2 | 586.2 | 600.3 |
| Diluted | 585.7 | 598.1 | 587.2 | 602.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.